115 related articles for article (PubMed ID: 31861249)
1. Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells.
Salcher S; Spoden G; Huber JM; Golderer G; Lindner H; Ausserlechner MJ; Kiechl-Kohlendorfer U; Geiger K; Obexer P
Cells; 2019 Dec; 9(1):. PubMed ID: 31861249
[TBL] [Abstract][Full Text] [Related]
2. A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma.
Salcher S; Spoden G; Hagenbuchner J; Führer S; Kaserer T; Tollinger M; Huber-Cantonati P; Gruber T; Schuster D; Gust R; Zwierzina H; Müller T; Kiechl-Kohlendorfer U; Ausserlechner MJ; Obexer P
Oncogene; 2020 Jan; 39(5):1080-1097. PubMed ID: 31591479
[TBL] [Abstract][Full Text] [Related]
3. FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3.
Rupp M; Hagenbuchner J; Rass B; Fiegl H; Kiechl-Kohlendorfer U; Obexer P; Ausserlechner MJ
Oncogene; 2017 Nov; 36(44):6190-6203. PubMed ID: 28869600
[TBL] [Abstract][Full Text] [Related]
4. C10ORF10/DEPP-mediated ROS accumulation is a critical modulator of FOXO3-induced autophagy.
Salcher S; Hermann M; Kiechl-Kohlendorfer U; Ausserlechner MJ; Obexer P
Mol Cancer; 2017 May; 16(1):95. PubMed ID: 28545464
[TBL] [Abstract][Full Text] [Related]
5. Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis.
Tan Y; Zhou Y; Zhang W; Wu Z; Xu Q; Wu Q; Yang J; Lv T; Yan L; Luo H; Shi Y; Yang J
Cell Oncol (Dordr); 2024 Feb; ():. PubMed ID: 38326640
[TBL] [Abstract][Full Text] [Related]
6. Nuclear FOXO3 predicts adverse clinical outcome and promotes tumor angiogenesis in neuroblastoma.
Hagenbuchner J; Rupp M; Salvador C; Meister B; Kiechl-Kohlendorfer U; Müller T; Geiger K; Sergi C; Obexer P; Ausserlechner MJ
Oncotarget; 2016 Nov; 7(47):77591-77606. PubMed ID: 27769056
[TBL] [Abstract][Full Text] [Related]
7. C10ORF10/DEPP, a transcriptional target of FOXO3, regulates ROS-sensitivity in human neuroblastoma.
Salcher S; Hagenbuchner J; Geiger K; Seiter MA; Rainer J; Kofler R; Hermann M; Kiechl-Kohlendorfer U; Ausserlechner MJ; Obexer P
Mol Cancer; 2014 Sep; 13():224. PubMed ID: 25261981
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase SIRT6 regulates chemosensitivity in liver cancer cells via modulation of FOXO3 activity.
Hu JQ; Deng F; Hu XP; Zhang W; Zeng XC; Tian XF
Oncol Rep; 2018 Dec; 40(6):3635-3644. PubMed ID: 30542728
[TBL] [Abstract][Full Text] [Related]
9. FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma.
Geiger K; Hagenbuchner J; Rupp M; Fiegl H; Sergi C; Meister B; Kiechl-Kohlendorfer U; Müller T; Ausserlechner MJ; Obexer P
Mol Biol Cell; 2012 Jun; 23(11):2226-34. PubMed ID: 22493319
[TBL] [Abstract][Full Text] [Related]
10. Unfavorable neuroblastoma prognostic factor NLRR2 inhibits cell differentiation by transcriptional induction through JNK pathway.
Sheikh A; Takatori A; Hossain MS; Hasan MK; Tagawa M; Nagase H; Nakagawara A
Cancer Sci; 2016 Sep; 107(9):1223-32. PubMed ID: 27357360
[TBL] [Abstract][Full Text] [Related]
11. Modulating FOXO3 transcriptional activity by small, DBD-binding molecules.
Hagenbuchner J; Obsilova V; Kaserer T; Kaiser N; Rass B; Psenakova K; Docekal V; Alblova M; Kohoutova K; Schuster D; Aneichyk T; Vesely J; Obexer P; Obsil T; Ausserlechner MJ
Elife; 2019 Dec; 8():. PubMed ID: 31789593
[TBL] [Abstract][Full Text] [Related]
12. Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.
Obexer P; Hagenbuchner J; Unterkircher T; Sachsenmaier N; Seifarth C; Böck G; Porto V; Geiger K; Ausserlechner M
Mol Biol Cell; 2009 Apr; 20(7):2041-8. PubMed ID: 19211844
[TBL] [Abstract][Full Text] [Related]
13. Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis.
Zhang L; Cai M; Gong Z; Zhang B; Li Y; Guan L; Hou X; Li Q; Liu G; Xue Z; Yang MH; Ye J; Chin YE; You H
J Clin Invest; 2017 Jun; 127(6):2159-2175. PubMed ID: 28436938
[TBL] [Abstract][Full Text] [Related]
14. Experimental evidences for miR-30b as a negative regulator of FOXO3 upregulated by kynurenine.
Duan ZQ; Li Y; Li L
Immunol Res; 2017 Oct; 65(5):1074-1082. PubMed ID: 28905195
[TBL] [Abstract][Full Text] [Related]
15. Loss of Forkhead Box O3 Facilitates Inflammatory Colon Cancer: Transcriptome Profiling of the Immune Landscape and Novel Targets.
Penrose HM; Cable C; Heller S; Ungerleider N; Nakhoul H; Baddoo M; Hartono AB; Lee SB; Burow ME; Flemington EF; Crawford SE; Savkovic SD
Cell Mol Gastroenterol Hepatol; 2019; 7(2):391-408. PubMed ID: 30718226
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA 195-5p Targets
Bai Y; Pan B; Zhan X; Silver H; Li J
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201585
[TBL] [Abstract][Full Text] [Related]
17. Vandetanib-induced inhibition of neuroblastoma cell migration and invasion is associated with downregulation of the SDF-1/CXCR4 axis and matrix metalloproteinase 14.
Ding X; Xiang L; Wang N; Zhao Z; Jin X; Sun Y; Duan W; Wang S; Jin X
Oncol Rep; 2014 Mar; 31(3):1165-74. PubMed ID: 24399074
[TBL] [Abstract][Full Text] [Related]
18. Lumican inhibits immune escape and carcinogenic pathways in colorectal adenocarcinoma.
Zang Y; Dong Q; Lu Y; Dong K; Wang R; Liang Z
Aging (Albany NY); 2021 Jan; 13(3):4388-4408. PubMed ID: 33493133
[TBL] [Abstract][Full Text] [Related]
19. Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.
Wu WR; Lin JT; Pan CT; Chan TC; Liu CL; Wu WJ; Sheu JJ; Yeh BW; Huang SK; Jhung JY; Hsiao MS; Li CF; Shiue YL
Theranostics; 2020; 10(2):707-724. PubMed ID: 31903146
[TBL] [Abstract][Full Text] [Related]
20. miR-590-3p Targets Cyclin G2 and FOXO3 to Promote Ovarian Cancer Cell Proliferation, Invasion, and Spheroid Formation.
Salem M; Shan Y; Bernaudo S; Peng C
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
